TRCT
IOVA icon

Tower Research Capital (TRC)’s Iovance Biotherapeutics IOVA Stock Holding History

Tower Research Capital (TRC)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205K Sell
58,416
-32,932
-36% -$105K 0.01% 1600
2025
Q4 		$249K Buy
91,348
+72,357
+381% +$167K 0.01% 1267
2025
Q3 		$41.2K Sell
18,991
-22,732
-54% -$53.7K ﹤0.01% 2686
2025
Q2 		$71.8K Buy
41,723
+30,668
+277% +$76.3K ﹤0.01% 2657
2025
Q1 		$36.8K Sell
11,055
-33,335
-75% -$172K ﹤0.01% 2452
2024
Q4 		$328K Buy
44,390
+21,157
+91% +$196K 0.01% 1336
2024
Q3 		$218K Sell
23,233
-10,466
-31% -$99.2K 0.01% 1554
2024
Q2 		$270K Buy
33,699
+7,751
+30% +$83.1K ﹤0.01% 1843
2024
Q1 		$385K Buy
25,948
+12,470
+93% +$145K 0.01% 1015
2023
Q4 		$110K Buy
13,478
+194
+1% +$1.01K ﹤0.01% 2585
2023
Q3 		$60.4K Buy
13,284
+1,547
+13% +$10.1K ﹤0.01% 2386
2023
Q2 		$82.6K Sell
11,737
-813
-6% -$5.82K ﹤0.01% 2179
2023
Q1 		$76K Sell
12,550
-18,989
-60% -$131K ﹤0.01% 2118
2022
Q4 		$201K Sell
31,539
-24,728
-44% -$193K 0.01% 1304
2022
Q3 		$539K Buy
56,267
+30,783
+121% +$355K 0.01% 1085
2022
Q2 		$281K Buy
25,484
+22,612
+787% +$296K 0.01% 1530
2022
Q1 		$48K Buy
2,872
+2,520
+716% +$39K ﹤0.01% 2765
2021
Q4 		$6K Sell
352
-302
-46% -$6.65K ﹤0.01% 5033
2021
Q3 		$17K Sell
654
-2,865
-81% -$67.5K ﹤0.01% 3867
2021
Q2 		$92K Sell
3,519
-83,836
-96% -$2.18M ﹤0.01% 2498
2021
Q1 		$2.77M Buy
87,355
+51,975
+147% +$2.15M 0.05% 371
2020
Q4 		$1.64M Buy
35,380
+31,705
+863% +$1.26M 0.05% 284
2020
Q3 		$121K Sell
3,675
-19,103
-84% -$586K ﹤0.01% 2996
2020
Q2 		$625K Buy
+22,778
New +$749K 0.03% 821
2020
Q1 		– Sell
-281
Closed -$8K – 3463
2019
Q4 		$8K Sell
281
-5,876
-95% -$134K ﹤0.01% 2451
2019
Q3 		$112K Buy
6,157
+4,957
+413% +$110K 0.01% 1286
2019
Q2 		$29K Buy
+1,200
New +$18.1K ﹤0.01% 1928
2018
Q4 		– Sell
-8,842
Closed -$99K – 4071
2018
Q3 		$99K Buy
8,842
+7,623
+625% +$108K 0.01% 1354
2018
Q2 		$16K Buy
1,219
+1,165
+2,157% +$17K ﹤0.01% 2554
2018
Q1 		$1K Sell
54
-618
-92% -$9.36K ﹤0.01% 3077
2017
Q4 		$5K Sell
672
-8,518
-93% -$68.4K ﹤0.01% 2889
2017
Q3 		$71K Buy
9,190
+8,911
+3,194% +$56.4K 0.01% 1668
2017
Q2 		$2K Buy
279
+79
+40% +$502 ﹤0.01% 2340
2017
Q1 		$1K Sell
200
-4,521
-96% -$33.1K ﹤0.01% 2799
2016
Q4 		$33K Buy
+4,721
New +$32.5K ﹤0.01% 1714
2016
Q3 		– Sell
-179
Closed -$1K – 4020
2016
Q2 		$1K Buy
+179
New +$1.12K ﹤0.01% 4162
2016
Q1 		– Sell
-414
Closed -$3K – 4517
2015
Q4 		$3K Sell
414
-2,107
-84% -$14.6K ﹤0.01% 3456
2015
Q3 		$14K Buy
+2,521
New +$19.6K ﹤0.01% 2030
2015
Q2 		– Sell
-3,765
Closed -$45K – 4697
2015
Q1 		$45K Buy
+3,765
New +$42.4K 0.01% 1558

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Tower Research Capital (TRC)'s IOVA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Iovance Biotherapeutics (IOVA) stake by 36% in Q1 2026, selling an estimated $105K and leaving 58,416 shares worth $205K. The position accounts for 0.01% of the portfolio, ranked #1600.

Tower Research Capital (TRC) first reported a position in IOVA in Q1 2015 and has held it in 39 quarters since. The position peaked at $2.77M in Q1 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Tower Research Capital (TRC) held 58,416 shares of Iovance Biotherapeutics worth $205K as of Q1 2026.
  • Tower Research Capital (TRC) sold 32,932 Iovance Biotherapeutics shares in Q1 2026, an estimated $105K.
  • Iovance Biotherapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1600 holding.
  • Tower Research Capital (TRC) first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 39 quarters since.
  • Tower Research Capital (TRC)'s Iovance Biotherapeutics position peaked at $2.77M in Q1 2021.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.